Secukinumab is
Ustekinumab (anti-IL-12/23) and secukinumab (anti-IL-17) monoclonal antibodies have shown promising efficacy in clinical trials, but have not yet been approved for use in Ankylosing Spondylitis. Reference: Harrison&;s Principles of Internal Medicine; kd tripathi 9th ed
Anti IL 1
Anti IL 6
Anti IL 17
Anti IL 23
General pharmacology